“利多卡因纳米药针”治疗膝骨关节炎患者的自身前后对照试验研究

注册号:

Registration number:

ITMCTR2024000169

最近更新日期:

Date of Last Refreshed on:

2024-08-05

注册时间:

Date of Registration:

2024-08-05

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

“利多卡因纳米药针”治疗膝骨关节炎患者的自身前后对照试验研究

Public title:

A self-controlled trial treating patients with knee osteoarthritis using a nano-enabled Lidocaine delivery acupuncture needle(Lidocaine nd-Acu)

注册题目简写:

利多卡因纳米药针治疗膝骨关节炎患者

English Acronym:

Treating patients with knee osteoarthritis using Lidocaine nd-Acu

研究课题的正式科学名称:

“利多卡因纳米药针”治疗膝骨关节炎患者的自身前后对照试验研究方案

Scientific title:

A self-controlled trial project treating patients with knee osteoarthritis using a nano-enabled Lidocaine delivery acupuncture needle(Lidocaine nd-Acu)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王鹏

研究负责人:

王鹏

Applicant:

Wang Peng

Study leader:

Wang Peng

申请注册联系人电话:

Applicant telephone:

+86 186 0002 1450

研究负责人电话:

Study leader's telephone:

+86 186 0002 1450

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangpeng@bjzhongyi.com

研究负责人电子邮件:

Study leader's E-mail:

wangpeng@bjzhongyi.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区美术馆后街23号首都医科大学附属北京中医医院

研究负责人通讯地址:

北京市东城区美术馆后街23号首都医科大学附属北京中医医院

Applicant address:

No. 23 Back Street of Art Gallery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Dongcheng District, Beijing

Study leader's address:

No. 23 Back Street of Art Gallery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Dongcheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

100010

研究负责人邮政编码:

Study leader's postcode:

100010

申请人所在单位:

首都医科大学附属北京中医医院

Applicant's institution:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024BL02-041-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

首都医科大学附属北京中医医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024/6/7 0:00:00

伦理委员会联系人:

刘声

Contact Name of the ethic committee:

Liu Sheng

伦理委员会联系地址:

北京市东城区美术馆后街69号北京中医医院景美办公区一楼113

Contact Address of the ethic committee:

Room 113 Jingmei Office Building, No. 69 Back Street of Art Gallery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Dongcheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8790 6734

伦理委员会联系人邮箱:

Contact email of the ethic committee:

liusheng@bjzhongyi.com

研究实施负责(组长)单位:

首都医科大学附属北京中医医院

Primary sponsor:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

研究实施负责(组长)单位地址:

北京市东城区美术馆后街23号首都医科大学附属北京中医医院

Primary sponsor's address:

No. 23 Back Street of Art Gallery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

北京市

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

首都医科大学附属北京中医医院

具体地址:

北京市东城区美术馆后街23号首都医科大学附属北京中医医院

Institution
hospital:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

Address:

No. 23 Back Street of Art Gallery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Dongcheng District, Beijing

经费或物资来源:

研究者自筹

Source(s) of funding:

by researcher

研究疾病:

膝骨关节炎

研究疾病代码:

Target disease:

knee osteoarthritis

Target disease code:

研究类型:

Study type:

治疗研究

Treatment study

研究设计:

Study design:

单臂

Single arm

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

通过患者自身前后疗效对照试验,观察“利多卡因纳米药针”治疗膝骨关节炎的疗效,包括膝关节的功能、疼痛控制和炎性反应的影响等;并观察“利多卡因纳米药针”治疗的安全性。

Objectives of Study:

From the self-controlled trial, to observe the effective of a nano-enabled Lidocaine delivery acupuncture needle(Lidocaine nd-Acu) treating patients with knee osteoarthritis, including the function of knee joint, pain control and inflammatory response, and to observe the treatment safety.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①年龄45-80岁; ②依据2014年英国国家卫生与临床优化研究所标准符合膝骨关节炎的诊断标准; ③近6个月Kellgren和Lawrecne的放射学诊断标准符合Ⅰ级~Ⅲ级; ④过去一周膝盖疼痛的严重程度平均≥4分(0分代表不痛,10分代表极端疼痛,共11个等级); ⑤男女不限; ⑥签署知情同意书,自愿参加本项目研究者。

Inclusion criteria

① age from 45 to 80 years old; ②patients meet the diagnostic criteria for knee osteoarthritis according to the 2014 National Institute for Health and Clinical Excellence criteria of the United Kingdom; ③ In recent 6 months, Kellgren and Lawrecne's radiological diagnostic criteria were in line with Grade I to Grade III; ④ The average severity of knee pain in the past week was ≥4 points (0 points representing no pain, 10 points representing extreme pain, a total of 11 scales); ⑤ male or female; ⑥ patients who signed informed consent and volunteer to participate in this project.

排除标准:

①有膝关节置换手术史; ②其他疾病引起的膝关节疼痛(如关节松动、感染、恶性肿瘤、自身免疫性疾病、外伤等)。合并急慢性膝关节周围滑膜炎、滑囊炎、韧带炎等软组织炎症的患者需经医生评估后决定是否入组; ③1年内曾接受关节镜检查或关节内注射; ④孕期或哺乳期妇女; ⑤严重急性/慢性器质性或精神疾病; ⑥凝血功能障碍(如血友病等); ⑦在过去三个月参加了别的临床研究。

Exclusion criteria:

① patients with a history of knee replacement surgery; ② knee pain caused by other diseases (e.g. joint loosening, infection, malignancy, autoimmune disease, trauma, etc.). Patients with acute and chronic periarticular synovitis, bursitis, ligamentitis and other soft tissue inflammation should be evaluated by doctors to decide whether to enter the group; ③ had undergone arthroscopy or intra-articular injection within 1 year; ④ pregnant or lactating women; ⑤ severe acute/chronic organic or mental illness; ⑥ coagulation disorders (such as hemophilia); ⑦ participated in other clinical studies in the past three months.

研究实施时间:

Study execute time:

From 2024-05-01

To      2026-06-30

征募观察对象时间:

Recruiting time:

From 2024-09-01

To      2025-12-31

干预措施:

Interventions:

组别:

治疗组

样本量:

5

Group:

treating group ( 1 group)

Sample size:

干预措施:

“利多卡因纳米药针”治疗

干预措施代码:

Intervention:

a nano-enabled Lidocaine delivery acupuncture needle(Lidocaine nd-Acu)

Intervention code:

样本总量 Total sample size : 5

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

北京

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

首都医科大学附属北京中医医院

单位级别:

三甲

Institution/hospital:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

Level of the institution:

Level III Grade A TCM hospital

测量指标:

Outcomes:

指标中文名:

膝关节运动功能Lysholm量表

指标类型:

次要指标

Outcome:

LKSS score

Type:

Secondary indicator

测量时间点:

治疗初次、末次(4周后第8次)、随访(治疗结束4周后)

测量方法:

量表评分

Measure time point of outcome:

before treatment, 4 weeks after treatment, 8 week after treatment

Measure method:

Scale Scoring

指标中文名:

西部安大略麦克马斯特大学骨关节炎指数可视化量表评分

指标类型:

主要指标

Outcome:

Western Ontario and McMaster Universities Osteoarthritis index,WOMAC score

Type:

Primary indicator

测量时间点:

治疗初次、末次(4周后第8次)、随访(治疗结束4周后)

测量方法:

量表评分

Measure time point of outcome:

before treatment, 4 weeks after treatment, 8 week after treatment

Measure method:

Scale Scoring

指标中文名:

中医症状分级量表

指标类型:

次要指标

Outcome:

TCM symptom scale score

Type:

Secondary indicator

测量时间点:

治疗初次、末次(4周后第8次)、随访(治疗结束4周后)

测量方法:

量表评分

Measure time point of outcome:

before treatment, 4 weeks after treatment, 8 week after treatment

Measure method:

Scale Scoring

指标中文名:

膝关节超声检查

指标类型:

次要指标

Outcome:

Knee joint ultrasonography

Type:

Secondary indicator

测量时间点:

治疗初次、末次(4周后第8次)、随访(治疗结束4周后)

测量方法:

超声检查

Measure time point of outcome:

before treatment, 4 weeks after treatment, 8 week after treatment

Measure method:

ultrasonography

指标中文名:

静脉血血浆炎症因子IL-1/IL-6/TNF-α

指标类型:

主要指标

Outcome:

Venous blood plasma inflammatory factor IL-1/IL-6/TNF-α

Type:

Primary indicator

测量时间点:

治疗初次、末次(4周后第8次)

测量方法:

抽取患者膝关节部位血液样本进行检测

Measure time point of outcome:

before treatment, 4 weeks after treatment

Measure method:

blood test

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 45
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

None

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

None

Blinding:

None

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

None

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集采用病例记录表(CRF表);数据管理为医院内部临床科研一体化平台。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection: using CRF; Data Management: the electronic data capture platform of the Beijing Hospital of TCM.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统